Page 12 - Emerging Technology News Today

U.S. lawmakers are raising alarms about what they see as America’s failure to compete with China in biotechnology. Theyre warning of risks to U.S. national security and commercial interests. But

Skydio and Aeroarc Partner to Advance Support for Government Customers in the Region

U.S. lawmakers are raising alarms about what they see as America’s failure to compete with China in biotechnology.

U.S. lawmakers are raising alarms about what they see as America's failure to compete with China in biotechnology, warning of the risks to U.S. national security and commercial interests. But as the two countries' rivalry expands into the biotech industry, some say that shutting out Chinese companies would only hurt the U.S. Biotechnology promises to…

U.S. lawmakers are raising alarms about what they see as America’s failure to compete with China in biotechnology

WASHINGTON (AP) — US lawmakers are raising alarms about what they see as America’s failure to compete with China in biotechnology, warning of the risks to US national security and commercial interests. But as the two countries’ rivalry expands into the biotech industry, some say that shutting out Chinese companies would only hurt the US. […]

Get latest articles and stories on World at LatestLY. US lawmakers are raising alarms about what they see as America's failure to compete with China in biotechnology, warning of the risks to US national security and commercial interests. But as the two countries' rivalry expands into the biotech industry, some say that shutting out Chinese companies would only hurt the US. World News | US Rivalry with China Expands to Biotech. Lawmakers See a Failure to Compete and Want to...

U.S. lawmakers are raising alarms about what they see as America’s failure to compete with China in biotechnology, warning of the risks to U.S. national security and commercial interests.

U.S. lawmakers are raising alarms about what they see as America’s failure to compete with China in biotechnology, warning of the risk...

Bills in the House and Senate aim to bar “foreign adversary biotech companies of concern” from doing business with federally funded medical providers.